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Abstract Hyperbaric oxygen (HBO) therapy is widely
used as an adjunctive treatment for various pathological
states, predominantly related to hypoxic and/or ischaemic
conditions. It also holds promise as an approach to over-
coming the problem of oxygen deficiency in the poorly
oxygenated regions of the neoplastic tissue. Occurrence of
local hypoxia within the central areas of solid tumours is
one of the major issues contributing to ineffective medical
treatment. However, in anti-cancer therapy, HBO alone
gives a limited curative effect and is typically not applied
by itself. More often, HBO is used as an adjuvant treatment
along with other therapeutic modalities, such as radio- and
chemotherapy. This review outlines the existing data
regarding the medical use of HBO in cancer treatment,
with a particular focus on the use of HBO in the treatment
of brain tumours. We conclude that the administration of
HBO can provide many clinical benefits in the treatment of
tumours, including management of highly malignant glio-
mas. Applied immediately before irradiation, it is safe and
well tolerated by patients, causing rare and limited side
effects. The results obtained with a combination of HBO/
radiotherapy protocol proved to be especially favourable
compared to radiation treatment alone. HBO can also
increase the cytostatic effect of certain drugs, which may
render standard chemotherapy more effective. The cur-
rently available data support the legitimacy of conducting
further research on the use of HBO in the treatment of
malignancies.
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Introduction
Hyperbaric oxygen (HBO) therapy is the use of oxygen
under elevated atmospheric pressure, that is, at a pressure
higher than the pressure found on the surface of the earth at
sea level, which is defined to be 1 atm [1]. Currently,
hyperbaric oxygenation is widely used as an adjunctive
treatment for various pathological states, predominantly
related to hypoxic and/or ischaemic conditions. The standard
protocol for hyperbaric oxygen therapy (HBOT) specifies
that patients breathe pure oxygen (*100 %) under pressure
between 1.5 and 2.5 atmospheres absolute (ATA), which is
defined as the sum of the atmospheric pressure and the gauge
pressure inside the hyperbaric chamber.
Oxygen is transported in blood to tissues by two dif-
ferent, well-known mechanisms: in complex with hae-
moglobin in red blood cells (RBCs) and dissolved in blood
plasma. Under normal atmospheric conditions, almost
97 % of the available haemoglobin is saturated with oxy-
gen. In contrast, plasma typically contains only 0.32 %
dissolved oxygen [2]. Thus, the administration of HBO
does not have a large effect on oxygen delivery via red
blood cells, but may improve haemoglobin-independent
transport. HBO has additional beneficial effects, refining
the elasticity of RBCs and reducing platelet aggregation,
which are especially important when the underlying cause
of the tissue hypoxia is cardiovascular in origin [1].
According to Henry’s law, if the partial pressure of oxygen
(pO2) rises, the oxygen content in tissues will also increase
[3]. Under higher pO2, the distance that oxygen diffuses is
increased. This phenomenon, along with the property that
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oxygen that is dissolved in fluid can reach areas that are
inaccessible to RBCs, allows one to imagine that breathing
hyperbaric 100 % oxygen may enable more efficient oxy-
genation of tissues with defective vascularization. HBOT
increases the amount of dissolved oxygen in the blood and
therefore enhances tissue oxygenation. HBOT has other
beneficial biochemical and cellular effects, including
reduction in oedema, constriction of blood vessels, acti-
vation of phagocytosis, neovascularization, and stimulation
of collagen production by fibroblasts. Consequently, HBO
finds application in the management of various pathologi-
cal states [3, 4]. Its beneficial role has been well established
in treatment of ischaemia and reperfusion injury [5–7].
HBO has also become widely used as an adjunctive treat-
ment for a variety of challenging medical conditions,
including arterial gas embolism [8, 9], carbon monoxide
poisoning [10–12], delayed radiation injury [13–16],
decompression sickness [17], problematic wounds [18],
bone fractures [19], and liver dysfunction [20]. HBO
appears to be generally safe for patients, as its side effects
are rare and oxygen toxicity appears primarily when it is
used at very high doses and for a longer duration than is
recommended [4].
This review outlines the existing data regarding the
medical use of HBO in cancer treatment, with a particular
focus on the use of HBOT in the treatment of brain tumours
and for prevention of late radiation injury in brain tissue.
Hyperbaric oxygen therapy in cancer treatment
One of the major issues contributing to ineffective medical
treatment of cancer is the occurrence of local hypoxia within
the central tumour areas. The application of HBOT may help
overcome the problem of oxygen deficiency in the poorly
oxygenated regions of the neoplastic tissue. To date, several
reviews on the use of HBO in cancer treatment have been
published [2, 21, 22]. The effect of this therapy on malig-
nancy has been unclear for a long time. The first and foremost
question was whether HBO inhibits tumour growth or per-
haps even enhances growth and the ability to form metas-
tases. This fear grew from the observation in previous
research studies that HBOT has a confirmed stimulatory
effect on the proliferation of fibroblasts and epithelial cells in
wound healing [3, 23]. Initially, the impact of hyperbaric
oxygen on cancer cells was not clearly defined, and the
results of early studies were controversial. McMillan et al.
[24] concluded that HBO suppresses the development of oral
carcinoma during its induction phase, whereas HBO might
promote tumour growth during the proliferation phase.
Recently, the similar results were obtained by Doguchi et al.
[25] who claimed that hyperbaric oxygenation enhances
tumour cells proliferation and therefore promotes
chemically induced skin carcinogenesis. Braks et al. [26]
conducted in vivo study on head and neck squamous cell
carcinoma in mouse model, which indicated that HBO alone
can enhance tumour growth, hypoxia, and vascular perme-
ability of non-irradiated tumours. No changes in time sur-
vival, metastasis, and malignancy of cancer were observed.
However, it should be emphasized that in the presented
studies time and frequency of oxygenation were greater than
in most experimentally used protocols. Nevertheless, the
current state of knowledge almost unequivocally states that
HBO is not only unconducive to further cancer development,
but even might reduce the main tumour mass [27, 28]. It has
been documented that HBO contributes to reduced tumour
hypoxia by raising the oxygen concentration in the blood
plasma. Brizel et al. [29] performed in vivo studies on rats
with implanted mammary adenocarcinoma. Animals divi-
ded into five groups were treated with inhaled normobaric or
hyperbaric (3 ATA) oxygen or with normobaric or hyper-
baric (3 ATA) carbogen (a gas mixture consisting of 95 % O2
and 5 % CO2). There was no significant improvement in
tumour oxygenation in groups exposed to either normobaric
oxygen or carbogen. However, positive results were
observed in the groups treated with high-pressure gases. The
latest analogical study was conducted by Thews and Vaupel
[30]. They tested an influence of normo- and hyperbaric
hyperoxygenation (pure oxygen or carbogen) on local
hypoxic regions occurrence and spatial pO2 distribution
using DS-sarcoma cell line injected subcutaneously in rats.
While in standard conditions (1 atm) hyperoxia only slightly
enhanced tumour oxygenation in comparison with normal
air, under pressure of 2 atm median pO2 was fivefold higher.
After hyperbaric oxygen as well as hyperbaric carbogen
administration, the spatial pO2 distribution profiles showed
almost absolute elimination of hypoxic regions, even in the
large tumours. However, HBO alone gives a limited curative
effect and is typically not applied by itself. More often, HBO
is used as an adjuvant treatment along with other therapeutic
modalities, such as radio-, chemo-, and photodynamic ther-
apy. Recently, Poff et al. [31] proposed also non-toxic,
metabolic anti-cancer therapy based on ketonic diet, ketone
supplementation, and hyperbaric oxygen combination.
When used during surgical procedures, HBO helps to speed
the convalescence and healing of wounds, and it minimizes
surgical pain [32].
Hyperbaric oxygen as an radiotherapy adjuvant
Radiotherapy (RT) utilizes the so-called classical oxygen
effect in tumour treatment. Upon exposure to radiation,
water molecules undergo radiolysis to form unstable hy-
drogen and hydroxyl radicals. Hydrogen radicals react with
molecular oxygen, yielding unstable perhydroxyl radicals
and hydrogen peroxide, which cause serious DNA strand
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damage and consequently lead to cell death [33]. Thus,
radiation treatment gives an optimal therapeutic result in
well-oxygenated tumour tissue. It was observed that mice
breathing pure 1 atm oxygen required a one-third smaller
dose of X-rays than mice that were breathing air to achieve
similar cancer regression [34]. HBO might play two pos-
sible roles when combined with RT: it may act as a
radiosensitizer, which enhances the effect of radiation, or it
may act as a therapeutic agent, reducing delayed radiation
injury [13–16]. A combination of HBO and radiotherapy
reduces tumour growth and improves local tumour control,
resulting in increased survival time [21, 35]. Watson et al.
[36] conducted clinical trial on 320 cervical carcinoma
patients to investigate the influence of radiation in com-
bination with HBO. Both local tumour control and patient
survival in the HBO group were significantly better than in
the control normobaric group. HBO had additional
impressive positive effects: oxygen therapy abolished
negative side effects of RT such as the accompanying
postradiation injury of normal tissue. Similar results were
obtained by Cade and McEwen, who enrolled 505 patients
with various types of cancer into a clinical trial investi-
gating the impact of HBO with radiotherapy [37]. Low
doses of radiation provided a weak therapeutic effect;
however, administration of a maximum dose along with
high-pressure oxygen improved the survival of the patients
with cervical or bronchial carcinoma in comparison with
patients who were irradiated in normal air. However, the
combined therapy did not affect patients with bladder
tumours [37]. Also, Henk et al. [38] obtained similar
negative results in a clinical trial of head and neck cancer
treatment in which HBO was used as a radiosensitizer. In
this trial, the survival time was similar regardless of whe-
ther the patients were breathing oxygen under elevated
pressure or normobaric air; however, local control of the
tumour was improved in the HBO-treated group. In further
studies, Henk et al. [39] observed a significant improve-
ment in patient survival (60 vs. 30 %) and tumour local
control (63 vs. 30 %) with radiation treatment in HBO or
air. Some other research groups, who conducted similar
independent experiments, noted a high prevalence of sev-
ere late complications [40–43]. Other recent reports sug-
gest that HBO treatment of patients with cancers of the
head and neck improves not only local tumour control but
also the overall outcome and that the side effects observed
previously were caused by excessive radiation doses per
fraction [35, 44].
Hyperbaric oxygen as a chemotherapy adjuvant
The mechanism of action of certain cytostatic drugs is
based on the production of reactive oxygen species (ROS).
ROS are formed as a result of oxidative stress in eukaryotic
cells, triggered by either insufficient or excessive levels of
oxygen in tissue, by radiation, by toxins, or by other
adverse factors [33]. ROS cause cellular damage via oxi-
dation, and this has been implicated in the pathogenesis of
many diseases. Increased production of ROS results in
DNA strand damage, apoptosis, and cell death. However,
the very frequent DNA mutations and impairment of
apoptosis lead to the development of highly anaplastic,
therapy-resistant, neoplastic cells that are capable of
causing local tumour recurrence and/or distant metastases.
Moreover, cancer cells develop effective mechanisms that
can help them to avoid the toxic effects of free radicals,
although the amount of ROS tolerated by neoplastic cells is
limited and above certain levels of oxidative stress or
during prolonged exposure, the self-defence mechanisms
become overwhelmed and cell death occurs [2]. Adminis-
tration of HBO can be therapeutically advantageous by
providing additional oxygen molecules and thereby
increasing chemotherapy-generated oxidative stress. In
addition, the transport of cytostatic agents is hindered by
poor tissue perfusion [2, 45]. HBO treatment overcomes
tissue hypoxia and promotes the development of new blood
vessels, which are then able to transport drug molecules,
thereby rendering the tumour cells more sensitive to
chemotherapeutic treatments. Several studies have been
conducted to examine the impact of hyperbaric oxygen as
an adjuvant agent for use with chemotherapy [46–60].
Kalns et al. [47] found that the effect of hyperbaric oxygen
on the proliferation and sensitivity to chemotherapy of
prostate cancer cells in vitro were dependent on the type of
cell line. Alazog et al. [46] examined the effect of cisplatin
treatment on ovarian cancer in mice xenografts under HBO
administration and found that HBO improved tumour
vascularization and, when combined with cisplatin,
diminished the tumour growth more effectively than cis-
platin alone. Similar results were also obtained by Sel-
vendiran et al. [58]; however, the authors believed that the
remarkable lessening of the tumour volume was mostly
associated with a dramatic reduction in overall body weight
in the cisplatin–HBO group. The probable cause was an
extreme increase in cisplatin toxicity triggered by hyper-
baric oxygen, which led the authors to conclude that the
combination of cisplatin and HBO should be avoided. In a
study performed on sarcoma cells in vivo, Takiguchi et al.
[48] assessed the therapeutic impact of HBO alone as well
as in combination with 5-fluorouracil (5-FU). They found
only a slight difference in tumour size between the control
and the HBO monotherapy group. In contrast, the combi-
nation of 5-FU and HBO together significantly slowed the
progression of tumour growth in comparison with the both
the control group and the group treated with administration
of 5-FU alone. Moreover, Stuhr et al. [50] observed that the
combination of 5-FU and HBO can cause regression of
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mammary tumours. Moen et al. evaluated the influence of
HBO on the uptake of 5-fluorouracil in an in vivo model of
mammary adenocarcinoma in rats. Three groups were
studied: a control group under atmospheric conditions
(defined by the authors as 1 bar), a group subjected to a
single HBO treatment (pO2 = 2 bar), and a group sub-
jected to repeated HBO treatments (pO2 = 2 bar, single
treatment every third day of experiment, four series in
total) [56]. Administration of a single dose of HBO caused
5-FU uptake into the tumour tissue to rise, as measured
immediately after oxygenation. No differences were
observed between the control group and the group with the
repeated HBO treatments, although it is noted that the
measurements of 5-FU uptake of the third group were
taken 24 h after the last HBO session, which may be too
long a time lag to observe any effects, as the pO2 increase
in tissue lasted for only about 60 min. Ohguri et al. [60]
proposed to combine hyperbaric oxygen with carboplatin
and mild hyperthermia (HT). After using carboplatin–mild
HT–HBO treatment sequence, the tumour growth was
slowed down and its size was reduced. It may be concluded
that HBO might be a promising chemotherapy adjuvant,
although its observed effectiveness depends strongly upon
the cytotoxic agent and the experimental conditions under
which is it measured, as well as the type of the tumour.
Hyperbaric oxygen therapy in malignant glioma
treatment
Gliomas are the most common primary brain tumours,
derived from astroglial cells. The highly malignant tumour,
glioblastoma (GBM), is characterized by aggressive biol-
ogy and infiltrative growth. The standard treatment for
glioblastoma includes surgical intervention, radiotherapy,
and chemotherapy. Despite continuous advancements in
treatment strategies, the prognosis for malignant glioma
patients remains poor. Median survival after GBM diag-
nosis is about 12 months and\15 % of patients live more
than 2 years [61]. Even the administration of temozolo-
mide (TMZ), the chemotherapeutic agent most commonly
used for gliomas, extends expected survival by only
2 months. It is thought that one of the pivotal factors
responsible for treatment failure is tumour hypoxia, which
is a state of reduced oxygen availability, or decreased
oxygen partial pressure, that restricts or even abolishes cell
functions [62]. Neoplastic proliferation induces rapid
tumour growth, associated with dysregulated and faulty
angiogenesis, resulting in a condition in which the neo-
plastic cells that are located in deeper regions of the tumour
are poorly supplied with oxygen [62, 63]. Such cells
migrate along the pathway of white matter to reach the
better oxygenated brain areas proximal to blood vessels.
Moreover, the hypoxia itself activates mechanisms
responsible for formation of abnormal blood vessels.
Therefore, invasion of neoplastic cells into the normal
brain tissue and faulty angiogenesis establish two so-called
vicious circles, in which a major causative role can be
ascribed to the occurrence of local hypoxic regions within
the tumour mass [63, 64]. Whereas hypoxia is toxic to
normal cells, causing their apoptotic and necrotic death,
neoplastic cells acquire the ability to develop defence
mechanisms that allow them to survive under conditions of
oxygen deprivation [2, 64]. The partial pressure of oxygen
differs within normal tissues and solid tumours and is
between 24 and 66 mmHg and 2.5–30 mmHg, respectively
[65]. Hypoxia triggers changes in the expression of pro-
teins involved in the cell cycle, proliferation, metabolism,
and apoptosis, which can exacerbate tumour malignancy
[2]. Consequently, a high level of hypoxia is considered to
be a negative prognostic factor with respect to patient
survival and response to treatment. Poor vascularization
and insufficient perfusion inside the tumour mass limit the
action of cytostatic agents, as they reach distant tumour
cells in lower concentrations than could otherwise be
expected. The administration of higher doses of cytostatic
drugs is not an alternative, due to their toxicity towards
normal, healthy cells [2]. Oxygen deprivation also results
in decreased efficiency of radiotherapy and phototherapy
[62, 66]. Therefore, to potentiate treatment, various
strategies to overcome tumour hypoxia have been pro-
posed, including inhibition of the expression of hypoxia
inducible factors (HIFs), increasing the ability of red blood
cells (RBCs) to carry oxygen (transfusions, administration
of erythropoietin), and the use of artificial oxygen carriers
(haemoglobin- or perfluorocarbon-based), radiosensitizers,
bioreductive drugs, and gene therapy [65–68]. One of the
most promising approaches to address the problem of
tumour hypoxia appears to be HBOT.
Only a few reviews addressing the use of HBOT in
patients with brain tumours have been published to date
[69]. Kohshi et al. [70] focused on the therapeutic effects of
HBO on brain tumours and tissue that has been injured by
radiation. In normal brain tissue, oxygen is observed at
approximately 25–50 mmHg [71, 72]. It is well docu-
mented that inside brain tumours, as in other solid tumours,
oxygen transport is seriously hindered and that local
hypoxic regions develop. As has been mentioned previ-
ously, the application of HBO increases oxygen transport
via blood plasma, independently from transport via hae-
moglobin. It has been experimentally demonstrated that
inhibition of oxygen saturation of haemoglobin to a level of
75 % induced the reduction in partial pressure of oxygen in
the cerebral tissue of rats that were breathing air, whereas
no pO2 changes were detected in rats that were breathing
high-pressure oxygen [73]. A positive impact of HBO on
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the oxygenation of brain tissue can be observed both in the
normal brain as well as in glioblastoma tissue; the oxygen
level can rise by as much as 100–115 % upon HBO
exposure [74]. Beppu et al. [75] measured peritumoral and
intratumoral pO2 in patients with glioblastoma under dif-
ferent conditions. The mean intratumoral pO2 level was
9.2 ± 5.8 mmHg, which is consistent with the findings
obtained in earlier studies [76, 77]. Hyperbaric oxygena-
tion caused an elevation in pO2 levels in the tissue most
closely surrounding the tumour and in the tumour interior,
and in both of these the pO2 level remained greater than
30 mmHg for 15 min after decompression [75].
Stuhr et al. [78] elucidated the effects of hyperbaric
oxygen alone on BT4C rat glioma xenografts in vivo.
Groups of eight animals were treated with 100 % O2 under
normobaric conditions or under higher pressure (of 2 bar),
or kept under normal air conditions as the control.
Hyperoxia (both normo- and hyperbaric) resulted in a 60 %
retardation of tumour growth in comparison with tumour
growth in the controls. Additionally, such tumours showed
a greater number of ‘‘empty’’ vacuole spaces and necrotic
areas, with 20 % more apoptotic cells than were observed
in control tumours, although it was notable that the pro-
liferation rate of cells remained unchanged. Under both
hyperoxia conditions, gene profile analysis revealed
induction of several pro-apoptotic genes (GzmG, Grid1,
Ceacam1) and proliferation inhibitors (Gap1gal), as well
as reduction in the expression of several anti-apoptotic
(Accn1, Nup62, Psen1), pro-proliferation (Hyal4, Sn5atp9),
and pro-angiogenic genes (Hif2a, Efna1). HBO did not
cause damage of normal tissues. Inconsistent observations
were made by Wang et al. [79]. Administration of HBO to
intracranial transplanted glioma mouse model caused
intensification of tumour growth as well as glioma cells
proliferation and angiogenesis. However, apoptosis of
neoplastic cells was significantly higher in HBO group than
in control. Ding et al. also pointed out to the potentially
hazardous consequences of HBO treatment like increased
tumour volume and angiogenesis, likewise apoptosis inhi-
bition [80]. Nevertheless, once again HBO procedures
employed to the mentioned studies were more intensive
than previously used. Such discrepancy might result also
from using the intracranial glioma models, while so far
experiments were carried out on subcutaneous transplanted
glioma cells.
Independently of uncertain beneficial effect of HBO
alone, its combination with radio- and/or chemotherapy
appeared advantageous. Chang investigated whether the
application of HBO during irradiation might improve the
curative effect of radiotherapy on glioma treatment [81]. The
median survival time of the patients in the HBO group was
38 weeks, in comparison with 31 weeks for patients in the
control group, and survival rates after 18 months were 28
and 10 %, respectively. Dowling et al. conducted a pilot
study to investigate the hypothesis that a combination of
perfluorochemicals with hyperbaric oxygen as adjunct for
radiation may have more beneficial impact than either
adjuvant therapy alone [82]. Sixteen of the 20 patients with
anaplastic astrocytoma or glioblastoma, who received Flu-
osol prior to irradiation in a HBO atmosphere, completed the
medical treatment with no symptoms of oxygen toxicity.
Despite enthusiasm generated by the outcomes of the trials
reviewed above, the effect of HBO simultaneously applied
with radiotherapy turned out to be complicated, as it resulted
in late side effects, including radiation necrosis and seizures
[83]. Kohshi et al. [83] proposed a variant approach, in which
patients were irradiated immediately after decompression
from the HBO conditions. Although reduction in high-grade
gliomas was observed in 33 % of the patients in the control
irradiated group, they all suffered recurrences and died
within 36 months after radiotherapy. In the group treated
with HBO and RT, more than 50 % tumour regression was
observed, and in four of the nine patients with anaplastic
astrocytoma the disappearance of the tumour lesions was
demonstrated by neuroimaging. Three patients from the
HBO-treated group died due to neoplastic development
during the period of observation. Kohshi et al. [84] further
investigated the optimal time window during which external
beam radiotherapy should be applied after hyperbaric oxy-
genation to achieve the desired therapeutic effect of treat-
ment of patients with malignant gliomas. The median
survival was observed to be twice as long in the hyperbaric
groups than in the control group. Greater than 50 % tumour
regression was observed in patients who received RT 15 min
after decompression. In the group receiving radiotherapy
30 min after decompression, no cancer regression occurred,
but the tumours were stable during an 11–14 month follow-
up period. The reason was postulated to be that the higher
oxygen pressure in the tumour lasted only for a short time
after oxygenation. Kohshi et al. [85] also examined the effect
of combining HBO with fractionated stereotactic radiother-
apy (FSRT) using a gamma unit. FSRT allows the precise,
and therefore less invasive, administration of lower doses of
radiation, which reduces damage to the normal tissue in the
vicinity of tumour. The median survival time of patients
treated with this protocol was observed to be 19 and
11 months for patients with anaplastic astrocytoma and
glioblastoma, respectively. Bu¨hler et al. [86] suggested that
photon irradiation applied after HBO can extenuate
glioblastoma cells survival and migration. Analysis of
prospective studies on the influence of HBO followed by RT
on high-grade glioma patients showed that proposed treat-
ment is safe and gives promising therapeutic results [87].
In Japan, malignant glioma is most commonly treated
with interferon beta, nimustine (ACNU), and radiation
(IAR therapy). Beppu et al. [88] tested a modified IAR
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therapy protocol in which radiation was preceded by the
administration of hyperbaric oxygen. A response to HBO/
IAR treatment was observed in 10 (50 %) of the patients
with glioblastoma and 3 (30 %) of the patients with
anaplastic astrocytoma (43 % in total). Only in two cases
was tumour progression noted. No correlation was made
between response rates and other prognostic factors
including age, Karnofsky performance scale (KPS), histo-
logical type of tumour, tumour size, and tumour location.
The results suggested that HBO/IAR may be advantageous
for patients with poor prognosis, who achieved comparable
results to those with good prognosis. Meanwhile, Ogawa
et al. conducted a prospective trial to investigate the fea-
sibility and efficacy of radiotherapy after hyperbaric oxy-
genation used together with chemotherapy [89]. Patients
with various kinds of malignant gliomas, including
glioblastoma, anaplastic astrocytoma, anaplastic oligoas-
trocytoma, and anaplastic oligodendroglioma, were
exposed to radiation treatment within 15 min after HBOT.
In addition, they received the cytostatic agents, procar-
bazine, nimustine, and vincristine. A 69 % positive
response was observed, with no instance of disease pro-
gression. The one- and two-year overall survival rates were
83 and 56 %, respectively. The same team observed similar
trends in further studies enlisting a larger group of patients
[90]. A positive response was observed in 57 % of the
cases, and the median survival time for patients with
glioblastoma was slightly prolonged from 11–15 months to
17.3 months in this study. However, acute toxicity devel-
oped in almost 48 % of the patients in both trials. Never-
theless, grade 4 haematological toxicity and late radiation
injuries were observed to be rare, and the use of this
method is not precluded. Over the long term, the median
survival time of patients treated with HBO followed by
radiotherapy in combination with chemotherapy was
20.2 months, with a 17.2 and 113.4 months median
observed for patients with glioblastoma and grade III
gliomas, respectively [91].
To investigate the influence of HBO on the distribution
of carboplatin in the brain, Suzuki et al. [92] used a rat
model in which this cytostatic agent was administered
intravenously. Under atmospheric conditions, they found
the level of carboplatin in rat brains to be undetectable, as
opposed to HBO-treated groups, in which the drug con-
centration could be established. The same research team
evaluated the effectiveness of carboplatin combined with
HBO for treatment of patients with gliomas [93]. HBO
treatment resulted in a prolongation of the carboplatin
mean residence time (MRT) in plasma. However, the
effects observed in patients were diverse (from complete
recovery or reduction of tumour mass to progression of
disease) and also difficult to interpret, due to the small
number of patients in each of the treatment groups. To
assess the impact of HBOT on the therapeutic effect of
temozolomide (TMZ), Dagistan et al. [94] conducted an
experimental study on rats that had been injected with C6
glioma cells. The results of this study suggested that the
combination of TMZ and HBO significantly diminishes
cell proliferation and angiogenesis and that it also stimu-
lates apoptosis of glioma cells, in comparison with the
control group and the group treated with TMZ alone. The
potential influence of HBO on TMZ cytotoxicity was
independently examined by Lu et al. [95] in in vitro trials.
The human glioma U251 cell line was incubated under
various therapeutic conditions: control, HBO alone, temo-
zolomide alone, and temozolomide plus HBO. Analysis of
the outcomes showed that combined TMZ/HBO therapy
provided significantly better cell growth inhibition, com-
pared to HBO alone, which elicited no changes. HBO also
induced apoptosis of neoplastic cells. Furthermore, the
mean rate of apoptosis was found to be over two and four
times greater in the TMZ-treated and the TMZ/HBO group,
respectively, compared to controls. A similar effect was
observed with regard to cell viability; the TMZ group
exhibited a fourfold increase in per cent of dead cells,
compared to the control group, while in the TMZ/HBO
group the percentage of dead cells was increased sixfold.
Decreased VEGF and MRP-1 protein levels that were
observed in the HBO and TMZ/HBO experimental groups
suggested that HBO may elicit its effect through two
pathways: inhibition of angiogenesis and diminution of
drug resistance.
Final conclusions
Hypoxic regions within the tumour mass play a major role
in tumour development and resistance to novel radio- and
chemotherapies. HBOT holds promise as an approach to
overcoming oxygen insufficiency by increasing the oxygen
supply to neoplastic tissue. Recent results strongly indicate
that HBO does not induce cancer growth, recurrence, or
metastasis. Indeed, HBO is observed to exert an inhibitory
effect on cancer cell proliferation and to stimulate cancer
cell apoptosis. However, the beneficial effect of HBO is
diverse, and it varies with the tumour type, malignancy,
size of the lesion, and the clinical state of the patient. It is
dependent on the specifics of the oxygenation protocol, and
consequently it is very important to establish the proper
moment of application, duration, pressure, and number of
doses.
We conclude that the administration of HBO can pro-
vide many clinical benefits in the treatment of tumours,
including management of highly malignant gliomas.
Applied immediately before irradiation, it is safe and well
tolerated by patients, causing rare and limited side effects.
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The results obtained with a combination of HBO/radio-
therapy protocol proved to be especially favourable com-
pared to radiation treatment alone. HBO can also increase
the cytostatic effect of certain drugs, which may render
standard chemotherapy more effective. The currently
available data support the legitimacy of conducting further
research on the use of HBO in the treatment of
malignancies.
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